Drug Trial Radar · NCT01233167
Effect of Different Anti-platelet Strategies on the Long-term Outcome After Sirolimus Drug-eluting Stent Implantation
Last checked: Nov 19, 2026Latest source record: Jul 20, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
5,232
Planned (sponsor's estimate)
Start
Aug 2011
Primary completion
Dec 2012
Study completion May 2013
Sponsor
- Lead sponsor
- Sir Run Run Shaw HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 3, 2010
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study aims to assess the effectiveness of dual antiplatelet therapy, aspirin alone versus steeply discontinued clopidogrel plus aspirin in preventing clinical MACE events.Our subject is beyond a 12-month period patients receiving sirolimus drug-eluting stent implantation.
Conditions
- Coronary Artery Disease
Interventions
clopidogrelDrug
clopidogrel 75 mg po per day for 12 months
placeboDrug
placebo 75mg po per day for 12 months
clopidogrel and placeboDrug
clopidogrel 50mg per day for 3 months,clopidogrel 25mg per day for 3 months,then placebo 75mg per day for 6 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- all cause mortalityTime frame: one year
- nonfatal myocardial infarctionTime frame: one year
- clinical-driven target vessel revascularizationTime frame: one year
- cardiac deathTime frame: one year
- stent thrombosisTime frame: one year
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.